Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
Phase II, multicentre, randomised, open-label study to assess the benefit of early
intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell
lymphoma (MCL)